- Details
- Axel Merseburger joins Alicia Morgans to discuss the results from the PRESIDE study presented at ASCO GU 2022. PRESIDE is a randomized, double-Blind, placebo-controlled, Phase 3b study of the efficacy and safety of continuing enzalutamide in chemotherapy-naïve, mCRPC patients treated with docetaxel plus prednisolone once they have progressed on enzalutamide. Clinical data demonstrate that using do...
|
- Details
- Alicia Morgans and Pedro Barata highlight real-world data understanding the metastatic prostate cancer setting, capturing data on patients treated for metastatic hormone-sensitive and then metastatic castration-resistant disease presented at ASCO GU 2022. Clinical trials presented over the past seven years have led to novel hormonal therapies as well as taxane based chemotherapy being approved for...
|
- Details
- Janet Kukreja joins Sam Chang to further highlight her presentation at GU ASCO 2022 focusing on clinical implications of molecular biomarkers in upper tract urothelial carcinoma (UTUC). Currently, the ideal marker does not exist, but we are on our way to more personalized medicine. Drs Chang and Kukreja highlight improved characterization, better identification, risk stratification, and then indiv...
|
- Details
- In this conversation with Sam Chang, Tracy Rose shares highlights from her GU ASCO 2022 presentation on novel therapies in bladder cancer and their toxicities, discussing the future of adjuvant and neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC). Biographies: Tracy L. Rose, MD, Assistant Professor of Medicine, Division of Oncology, The University of North Carolina at Ch...
|
- Details
- Charles Ryan is joined by Michael Korn, the Chief Medical Officer of Caris Life Sciences, to discuss the study results assessing the comprehensive genomic profiling of penile squamous cell carcinoma (SCC) and the impact of HPV status on immune-checkpoint inhibition-related biomarkers. Using the Caris Life Sciences dataset, this study aimed to report the landscape of somatic alterations and ICI-rel...
|
- Details
- Neeraj Agarwal joins Alicia Morgans for a conversation on the TALAPRO-3 data presented at the GU ASCO 2022 meeting. The TALAPRO-3 trial is a phase 3 trial assessing enzalutamide plus talazoparib (TALA) versus placebo plus enzalutamide (ENZA) in men with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC) and compares the combination of TALA plus ENZA versus placebo plus ENZA i...
|
- Details
- Jonathan Rosenberg joins Alicia Morgans to discuss the results of the BAYOU trial. BAYOU is a randomized phase II study examining durvalumab and olaparib as first-line therapy in platinum-ineligible patients with unresectable stage IV urothelial carcinoma. Biographies: Jonathan E. Rosenberg, MD, Chief of the Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; and the Enno W....
|
- Details
- Sam Chang and Jeanny Aragon-Ching discuss treatment and survival differences in patients with urothelial versus non-urothelial bladder and upper tract carcinomas an analysis from the National Cancer Database (NCDB). There is an increased need for learning more about urothelial and non-urothelial cancers because non-urothelial cancers typically have been known to have a worse prognosis than urothel...
|
- Details
- Alicia Morgans is joined by Shahneen Sandhu to discuss her presentation at GU ASCO 2022 on targeting prostate-specific membrane antigen (PSMA), specifically lutetium, and the next wave of novel radiopharmaceuticals. Dr. Sandhu's presentation focused on where we go with PSMA treatments in the future. Biographies: Shahneen Sandhu, MD, Ph.D., MBBS, FRACP, Associate Professor, Consultant Medical Oncol...
|
- Details
- Alicia Morgans and Arun Azad discuss a post hoc analysis of the ARCHES trial data presented at GU ASCO 2022 of overall survival by disease volume and progression to M1 HSPC after initial diagnosis with localized disease or presentation of de novo mHSPC at initial diagnosis. Biographies: Arun Azad, MBBS, PhD, FRACP, Medical Oncologist, Associate Professor, Department of Medicine, Peter MacCallum Ca...
|
